CoChat

Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress

Open access
Thomas, Anish, Takahashi, Nobuyuki, Rajapakse, Vinodh N., Zhang, Xiaohu, Sun, Yilun, Ceribelli, Michele, Wilson, Kelli M., Zhang, Yang, Beck, Erin, Sciuto, Linda, Nichols, Samantha, Elenbaas, Brian, Puc, Janusz, Dahmen, Heike, Zimmermann, Astrid, Varonin, Jillian, Schultz, Christopher W., Kim, Sehyun, Shimellis, Hirity, Desai, Parth, Klumpp-Thomas, Carleen, Chen, Lu, Travers, Jameson, McKnight, Crystal, Michael, Sam, Itkin, Zina, Lee, Sunmin, Yuno, Akira, Lee, Min-Jung, Redon, Christophe E., Kindrick, Jessica D., Peer, Cody J., Wei, Jun S., Aladjem, Mirit I., Figg, William Douglas, Steinberg, Seth M., Trepel, Jane B., Zenke, Frank T., Pommier, Yves, Khan, Javed, Thomas, Craig J. · 2021 · Cancer Cell
Cited by 173

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Summary Small-cell neuroendocrine cancers (SCNCs) are recalcitrant cancers arising from diverse primary sites that lack effective treatments. Using chemical genetic screens, we identified inhibition of ataxia telangiectasia and Rad3-related (ATR), primary activator of the replication stress response, and topoisomerase I (TOP1), nuclear enzyme that suppresses genomic instability, as synergistically cytotoxic in small cell lung cancer (SCLC). In a proof-of-concept study, we combined M6620 (berzosertib), first-in-class ATR inhibitor, and TOP1 inhibitor topotecan in patients with relapsed SCNCs. Objective response rate among patients with SCLC was 36% (9/25), achieving the primary efficacy endpoint. Durable tumor regressions were observed in patients with platinum-resistant SCNCs, typically fatal within weeks of recurrence. SCNCs with high neuroendocrine differentiation, characterized by enhanced replication stress, were more likely to respond. These findings highlight replication stress as a potentially transformative therapeutic SCNC vulnerability, paving the way for rational patient selection in these cancers, now treated as a single disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.02.014

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 173

Metadata

Authors
Thomas, A., Takahashi, N., Rajapakse, V. N., Zhang, X., Sun, Y., Ceribelli, M., Wilson, K. M., Zhang, Y., Beck, E., Sciuto, L., Nichols, S., Elenbaas, B., Puc, J., Dahmen, H., Zimmermann, A., Varonin, J., Schultz, C. W., Kim, S., Shimellis, H., Desai, P., Klumpp-Thomas, C., Chen, L., Travers, J., McKnight, C., Michael, S., Itkin, Z., Lee, S., Yuno, A., Lee, M.-J., Redon, C. E., Kindrick, J. D., Peer, C. J., Wei, J. S., Aladjem, M. I., Figg, W. D., Steinberg, S. M., Trepel, J. B., Zenke, F. T., Pommier, Y., Khan, J., & Thomas, C. J.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2021-04
Volume
39
Issue
4
Pages
566-579.e7
ISSN
1535-6108 (ISSN-L)
OpenAlex
W3154101159
Cited by
173
References
14
FWCI
10.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. https://app.cochat.ai/papers/10.1016/j.ccell.2021.02.014
The paper
Thomas, A., Takahashi, N., Rajapakse, V. N., Zhang, X., Sun, Y., Ceribelli, M., Wilson, K. M., Zhang, Y., Beck, E., Sciuto, L., Nichols, S., Elenbaas, B., Puc, J., Dahmen, H., Zimmermann, A., Varonin, J., Schultz, C. W., Kim, S., Shimellis, H., . . . Thomas, C. J. (2021). Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell. https://doi.org/10.1016/j.ccell.2021.02.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.